Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 702701, 8 pages
http://dx.doi.org/10.1155/2014/702701
Clinical Study

Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment

1Department of Rheumatology and Internal Medicine, “Sfanta Maria” Hospital, Bulevardul Ion Mihalache nr 37-39, 011172 Bucharest, Romania
2“Carol Davila” University of Medicine, Bucharest, Romania
3Biology Faculty, Bucharest University, Bucharest, Romania
4Biology Faculty, “Alexandru Ioan Cuza” University, Iasi, Romania

Received 28 February 2014; Revised 7 May 2014; Accepted 7 May 2014; Published 20 May 2014

Academic Editor: Frank Buttgereit

Copyright © 2014 Diana Mazilu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [24 citations]

The following is the list of published articles that have cited the current article.

  • Thomas Doerner, and Jonathan Kay, “Biosimilars in rheumatology: current perspectives and lessons learnt,” Nature Reviews Rheumatology, vol. 11, no. 12, pp. 713–724, 2015. View at Publisher · View at Google Scholar
  • Inesa Arstikyte, Giedre Kapleryte, Irena Butrimiene, and Algirdas Venalis, “ Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients ,” BioMed Research International, vol. 2015, pp. 1–10, 2015. View at Publisher · View at Google Scholar
  • Benjamin Chaigne, and Loïc Guillevin, “New therapeutic approaches for ANCA-associated vasculitides,” La Presse Médicale, 2016. View at Publisher · View at Google Scholar
  • Mohsin El Amrani, Marcel P.H. van den Broek, Camiel Göbel, and Erik M. van Maarseveen, “Quantification of active infliximab in human serum with liquid chromatography–tandem mass spectrometry using a tumor necrosis factor -alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard: A target-based, sensitive and cost-effective method.,” Journal of Chromatography A, 2016. View at Publisher · View at Google Scholar
  • Anette Karle, Sebastian Spindeldreher, and Frank Kolbinger, “Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity,” mAbs, pp. 1–15, 2016. View at Publisher · View at Google Scholar
  • Delia Goletti, Valentina Marino, Giuseppe Maria Milano, Raffaele Scarpa, Andrea Matucci, Alessandra Vultaggio, Daniele Cammelli, Fabrizio Cantini, Giuliano Tocci, and Enrico Maggi, “Influence of anti-TNF immunogenicity on safety in rheumatic disease: A narrative review,” Expert Opinion on Drug Safety, vol. 15, pp. 3–10, 2016. View at Publisher · View at Google Scholar
  • Umberto Basile, Francesca Gulli, Laura Gragnani, Cecilia Napodano, Krizia Pocino, Gian Ludovico Rapaccini, Michele Mussap, and Anna Linda Zignego, “Free light chains: Eclectic multipurpose biomarker,” Journal of Immunological Methods, 2017. View at Publisher · View at Google Scholar
  • Alfons A. Den Broeder, Noortje Van Herwaarden, Bart J.F. Van Den Bemt, Maike H.M. Wientjes, and Cornelis Kramers, “Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review,” Expert Opinion on Drug Metabolism and Toxicology, vol. 13, no. 8, pp. 843–857, 2017. View at Publisher · View at Google Scholar
  • Frédéric Medina, Chamaida Plasencia, Philippe Goupille, Alejandro Balsa, Denis Mulleman, and David Ternant, “Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis,” Therapeutic Drug Monitoring, vol. 39, no. 4, pp. 364–369, 2017. View at Publisher · View at Google Scholar
  • Valentina Pecoraro, Elena De Santis, Alessandra Melegari, and Tommaso Trenti, “The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis,” Autoimmunity Reviews, 2017. View at Publisher · View at Google Scholar
  • Manca Ogrič, Matic Terčelj, Sonja Praprotnik, Matija Tomšič, Borut Božič, Snezna Sodin-Semrl, and Saša Čučnik, “Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits,” Immunologic Research, vol. 65, no. 1, pp. 172–185, 2017. View at Publisher · View at Google Scholar
  • Carla Bastida, Virginia Ruíz, Mariona Pascal, Jordi Yagüe, Raimon Sanmartí, and Dolors Soy, “Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?,” British Journal of Clinical Pharmacology, vol. 83, no. 5, pp. 962–975, 2017. View at Publisher · View at Google Scholar
  • Stefania Lombardi, Cristina Bernardoni, Daniela Bertolucci, Riccardo Cecchetti, Francesca De Giorgio, GianLuigi Occhipinti, Andrea Palagi, Gloria Bertacca, Isabella Giannelli, Elena Bonomi, Marco Friggeri, and Giancarlo Tartarelli, “Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy,” Journal of Autoimmunity and Cell Responses, vol. 4, no. 1, pp. 1, 2017. View at Publisher · View at Google Scholar
  • Oliver von Richter, Andrej Skerjanec, Miguel Afonso, Heike Woehling, Maria Velinova, Dmitrij Kollins, Lars Macke, Guido Wuerth, Sabine Sanguino Heinrich, Johann Poetzl, and Annelize Koch, “GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes,” British Journal of Clinical Pharmacology, vol. 83, no. 4, pp. 732–741, 2017. View at Publisher · View at Google Scholar
  • Noriko Iwamoto, Kotoko Yokoyama, Megumi Takanashi, Atsushi Yonezawa, Kazuo Matsubara, and Takashi Shimada, “Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum,” Pharmacology Research & Perspectives, vol. 6, no. 4, pp. e00422, 2018. View at Publisher · View at Google Scholar
  • Alfons A. Den Broeder, Noortje Van Herwaarden, and Bart J.F. Van Den Bemt, “Therapeutic drug monitoring of biologicals in rheumatoid arthritis: A disconnect between beliefs and facts,” Current Opinion in Rheumatology, vol. 30, no. 3, pp. 266–275, 2018. View at Publisher · View at Google Scholar
  • María Martín-López, Loreto Carmona, Alejandro Balsa, Jaime Calvo-Alén, Raimon Sanmartí, Jesús Tornero, and José Rosas, “Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review,” Rheumatology International, 2018. View at Publisher · View at Google Scholar
  • Evelyne Correia, Maxime Tenon, Frank Kolbinger, Sebastian Spindeldreher, Anette Karle, Philip Jarvis, and Bernard Maillère, “Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab,” Dermatology and Therapy, vol. 8, no. 1, pp. 57–68, 2018. View at Publisher · View at Google Scholar
  • B. Gorovits, D. J. Baltrukonis, I. Bhattacharya, M. A. Birchler, D. Finco, D. Sikkema, M. S. Vincent, S. Lula, L. Marshall, and T. P. Hickling, “Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab,” Clinical & Experimental Immunology, 2018. View at Publisher · View at Google Scholar
  • Chad J. Pickens, Stephanie N. Johnson, Melissa M. Pressnall, Martin A. Leon, and Cory J. Berkland, “Practical Considerations, Challenges, and Limitations of Bioconjugation via Azide–Alkyne Cycloaddition,” Bioconjugate Chemistry, 2018. View at Publisher · View at Google Scholar
  • Laura Magill, Marsilio Adriani, Véronique Berthou, Keguan Chen, Aude Gleizes, Salima Hacein-Bey-Abina, Agnes Hincelin-Mery, Xavier Mariette, Marc Pallardy, Sebastian Spindeldreher, Natacha Szely, David A. Isenberg, Jessica J. Manson, Elizabeth C. Jury, and Claudia Mauri, “Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients,” Frontiers in Immunology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • K. Reich, A. Blauvelt, A. Armstrong, R.G. Langley, A. de Vera, F. Kolbinger, S. Spindeldreher, M. Ren, and G. Bruin, “Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years,” Journal of the European Academy of Dermatology and Venereology, 2019. View at Publisher · View at Google Scholar
  • Shunsuke Ito, Tatsuya Ikuno, Masayuki Mishima, Mariko Yano, Toshiko Hara, Taichi Kuramochi, Zenjiro Sampei, Tetsuya Wakabayashi, Mitsuyasu Tabo, Shuichi Chiba, and Chiyomi Kubo, “ In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity ,” Journal of Immunotoxicology, vol. 16, no. 1, pp. 125–132, 2019. View at Publisher · View at Google Scholar
  • Rebollo, Munoz, Calvo, Sanchez-Hernandez, and Martin-Suarez, “Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases,” Annals of Clinical Biochemistry, vol. 56, no. 1, pp. 28–41, 2019. View at Publisher · View at Google Scholar